Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Plus, check out our handy semaglutide weight loss dosage chart for an easy-to-follow overview ... 1 receptor agonist to help with weight loss. Zepbound (tirzepatide) and Saxenda (liraglutide ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

Results from a separate trial that were released in 2022 showed patients taking a high dose of Lilly's (LLY.N), opens new tab Zepbound saw more than 20% weight loss. "The results give us greater ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The Hims & Hers ad presents more affordable versions of the popular weight-loss drugs Ozempic ... And in the case of Zepbound, patients can purchase the drug directly from the manufacturer ...

That compared with 15.6% weight loss among people taking the currently approved 2.4-mg dose, and 3.9% among people taking placebo, Novo said Friday. Zepbound led to 20.9% weight loss over 72 weeks ...

People who stayed on this dose lost around 20% of their baseline weight over a 72 week period. The findings exceed the typical weight loss results seen with the existing semaglutide-based drugs ...